XtalPi and Singapore's EDDC Forge Strategic Collaboration to Advance AI-Powered Drug Discovery for Non-Small Cell Lung Cancer

XtalPi Collaborates with Singapore's National Drug Discovery Platform to Develop More Effective Precision Treatment Solutions for Global Lung Cancer Patients

Shenzhen, China and SingaporeDecember 20, 2022PR Newswire -- Recently, XtalPi and Singapore's national drug discovery platform, the Experimental Drug Development Centre (EDDC), have reached a strategic cooperation. They will focus on the non-small cell lung cancer (NSCLC) target selected by EDDC, using a three-in-one R&D model driven by artificial intelligence (AI), automated experiments, and expert experience to promote drug discovery, providing new candidate drugs for precise treatment of lung cancer. As Singapore's national drug development platform, EDDC is managed by the Agency for Science, Technology and Research (A*STAR), aiming to strengthen Singapore's R&D capabilities in the biopharmaceutical field and promote the transformation of R&D achievements.

Lung cancer is the second most common cancer globally and the leading cause of cancer-related deaths. According to statistics from the international academic journal *Annals of Oncology*, non-small cell lung cancer accounts for over 80% of all lung cancer cases, and its incidence continues to rise worldwide. The global market size for non-small cell lung cancer therapies is projected by the international market research firm Research and Markets to exceed $20 billion by 2027. Despite the growing number of new drug studies and investment scale, there remains a significant unmet clinical need for more effective targeted treatment options for patients with non-small cell lung cancer.

In the new drug R&D project targeting non-small cell lung cancer (NSCLC), XtalPi will utilize its self-developed "Intelligent and Automated Drug Discovery System" to generate and screen millions of molecules during the drug design phase, predicting the most promising drug molecules. These molecules will undergo rapid iterative optimization through validation in automated laboratories, ultimately leading to more ideal preclinical candidate compounds (PCC). In this process, EDDC will provide valuable insights and research data on novel NSCLC targets, further accelerating the drug discovery process and advancing the project toward key milestones.

Dr. Shuhao Wen, Co-founder and Chairman of XtalPi, said: "We are honored to establish a strategic partnership with EDDC. XtalPi is committed to accelerating the speed, scale, novelty, and success rate of drug discovery through cutting-edge technologies such as artificial intelligence and automation, serving patients worldwide. Through this collaboration, we hope to further expand and strengthen our cooperation with top global research institutions, jointly advancing innovation and the transformation of drug discovery under the guidance of clinical needs, contributing to extending patients' lives and improving their quality of life."

EDDC CEODamian O'Connell"The collaboration with XtalPi allows us to translate science and research into effective targeted therapies for the treatment of cancer," the professor said. "With XtalPi's expertise in artificial intelligence and automation technology, we believe this partnership holds the potential to accelerate the development of much-needed targeted treatments for patients with NSCLC."